Can an Ethics Committee Suspend or Withdraw Approval After a Study Has Started?

Can Ethics Approval Be Taken Away After Researchers Have Already Started?

Researchers sometimes think of ethics approval as a final permission: once the approval letter arrives and data collection begins, the committee's decision is settled unless the researchers themselves request a change.

That is not how several major research-oversight systems work. Approval can carry continuing conditions, and significant problems discovered after research begins can trigger further review. In some frameworks, an ethics committee or institutional review board has explicit authority to suspend or terminate approval.

The reasons can include serious failures to follow ethics requirements or unexpected serious harm to participants. What suspension or termination means in practice, however, requires more nuance than simply saying, “The study must stop.” Existing participants, safety follow-up, ongoing interventions, data, and other obligations may still need careful management.

Yes, Approval Can Be Suspended or Terminated Under Some Ethics Frameworks

Ethics Oversight Does Not Necessarily End When Initial Approval Is Granted

Some Regulations Explicitly Give IRBs Authority to Suspend or Terminate Approval

Under the U.S. Common Rule, an IRB has authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to participants. Any suspension or termination must include the reasons for the IRB's action. FDA regulations establish parallel authority for FDA-regulated research.

These are U.S. regulatory requirements and should not be presented as universal rules for every ethics committee worldwide. Other jurisdictions may use different terminology, legal authority, procedures, or thresholds. Researchers should therefore consult the rules governing the particular study.

Suspension and Termination Are Not Quite the Same Thing

A suspension generally stops some or all approved research activity while a problem is investigated, evaluated, or corrected. OHRP guidance notes that suspension may be appropriate when a significant issue is first identified, such as an allegation of serious noncompliance or a participant-safety concern requiring further investigation.

Termination is more final: the ethics committee ends its approval of the research. What investigators must do next depends on the committee's decision and the circumstances of the study.

Some institutions may use terms such as withdrawal of approval, hold, restriction, or suspension differently. The formal notice governing the study should therefore be read carefully rather than relying on the ordinary-language meaning of the label.

Failure to Follow Ethics Committee Requirements Can Trigger Action

Approval authorizes research under particular conditions. If investigators repeatedly or seriously fail to conduct the study in accordance with those requirements, the ethics committee may need to intervene.

Examples could include unauthorized protocol changes, persistent use of unapproved procedures, significant informed-consent failures, repeated eligibility departures, failure to report required events, or continuing conduct after approval has lapsed where the applicable system requires active approval.

Not every isolated deviation results in suspension. The seriousness, recurrence, consequences, corrective response, and applicable institutional procedures matter.

Unexpected Serious Harm Can Also Trigger Suspension or Termination

A study can be conducted exactly as approved and still reveal risks that were not previously understood. Ethics approval is based on the evidence available when the study is reviewed; new safety information can change that assessment.

OHRP guidance describes unanticipated problems as events or information that are unexpected, related or possibly related to the research, and suggest greater risk of harm than was previously known or recognized. It also notes the IRB's authority to suspend or terminate research associated with unexpected serious harm.

Suspension in such circumstances is not necessarily a finding that researchers behaved improperly. The ethical conditions supporting continued participation may simply have changed as new evidence emerged.

Suspension Can Be Used While Facts Are Still Being Established

Sometimes the committee does not yet know whether a serious allegation is correct. Continuing enrollment or study procedures while investigating could nevertheless expose participants to unnecessary uncertainty or risk.

OHRP guidance specifically recognizes that suspension can be appropriate while allegations of serious noncompliance or participant-safety issues undergo investigation and evaluation.

This makes suspension partly a protective tool. It can create space to establish facts without allowing potentially problematic research activity to continue unchecked.

A Suspension Does Not Necessarily Mean Every Study Activity Stops

This point is particularly important for studies in which participants are already receiving interventions, treatment, monitoring, or follow-up.

Stopping every activity immediately could itself create risk. A participant may require safety assessments, tapering of an intervention, follow-up for an adverse event, or continued access to an intervention while an orderly transition is arranged.

The U.S. Common Rule does not itself provide a detailed rule defining when research procedures should continue in the “best interests” of participants after research has been suspended or terminated. A 2024 SACHRP recommendation specifically discusses this gap and proposes a framework for considering whether continued research interventions or procedures may be appropriate for enrolled participants. The recommendation is advisory rather than regulation.

Researchers should therefore follow the suspension notice and obtain direction from the responsible ethics committee, institution, sponsor, and appropriate clinical personnel rather than deciding independently which suspended activities may continue.

New Enrollment and Existing Participants Can Be Treated Differently

A committee may stop new enrollment while allowing specified follow-up of participants already enrolled. It may suspend only a particular procedure or site rather than the entire project. Alternatively, the problem may require a complete halt.

OHRP guidance on continuing review notes that in multicenter research a local IRB may suspend or terminate approval only at its own institution when the problem is site-specific, while a central IRB may take action at one site or across all relying institutions depending on the nature of the problem.

The scope of the action should therefore be taken from the committee's actual determination rather than assumed.

Suspension Should Trigger an Immediate Participant-Management Plan

When approval is suspended, researchers need to know which activities must stop, which may continue, and what must happen to participants already enrolled.

Questions may include whether participants need to be informed, whether study interventions should continue, how adverse events will be monitored, whether follow-up visits remain necessary, what happens to participants awaiting study procedures, and how data or specimens already collected should be handled.

OHRP guidance states that an IRB considering suspension may also consider whether participants should be notified about the suspension and its reasons and, if so, when notification should occur.

Suspension Can Sometimes Be Lifted

Because suspension can be temporary, the committee may establish conditions that must be satisfied before research resumes. These could involve protocol modifications, retraining, enhanced monitoring, revised consent materials, replacement of personnel, improved safety procedures, or other corrective measures appropriate to the problem.

Researchers should not restart merely because they believe the problem has been corrected. Resumption should occur only when the authority that imposed the suspension permits it under the applicable process.

Persistent Serious Noncompliance Can Have Broader Consequences

In clinical trials, ICH E6(R3) requires sponsors to take appropriate and proportionate action to secure compliance when noncompliance with the protocol, standard operating procedures, GCP, or regulatory requirements occurs. Where serious noncompliance is identified, notification to regulatory authorities or the IRB/IEC may be required, and persistent significant noncompliance despite remediation can lead the sponsor to consider terminating an investigator's, institution's, or service provider's participation in the trial.

This is sponsor action rather than identical to an ethics committee terminating approval, but it illustrates an important point: serious post-approval problems can trigger several overlapping oversight mechanisms.

Suspension or Termination Must Be Communicated Through Formal Procedures

Under U.S. HHS and FDA regulations, suspension or termination of IRB approval must include a statement of the reasons for the action and must be promptly reported to specified parties. FDA requires reporting to the investigator, appropriate institutional officials, and FDA for FDA-regulated research; HHS requirements similarly establish reporting obligations within their jurisdiction.

This means suspension is not supposed to be a mysterious verbal instruction floating around the department. The formal action and its basis should be documented according to the applicable process.

Institutional Authorities May Have Separate Powers

Ethics committee authority is not necessarily the only institutional authority relevant to research. Under the U.S. Common Rule, institutional officials may subject IRB-approved research to further review and may disapprove it, but they may not approve non-exempt human-subjects research that has not been approved by the IRB.

Other research systems may divide authority differently among ethics committees, institutions, regulators, sponsors, data safety bodies, and funders. Researchers should therefore distinguish “the ethics committee suspended approval” from other situations in which a sponsor or institution pauses a study under separate authority.

When Repeated Consent Problems Lead to a Temporary Suspension

The suspension in this example is not simply punishment for paperwork failure. Its immediate purpose is to prevent additional participants from entering a consent process whose reliability is currently uncertain.

Common Misunderstandings About Suspension or Termination of Ethics Approval

If Approval Is Suspended, Read the Scope Before Taking Further Research Action

The first practical task is to understand precisely what has been suspended or terminated. Do not rely on secondhand descriptions such as “the IRB stopped the study.” Obtain the formal determination and identify what it requires.

Researchers do not need to wait for an ethics committee to force every pause. If emerging conditions make continued research ethically questionable, the research team itself should consider whether voluntarily pausing the study is warranted. In more fundamental cases, the relevant question becomes whether the ethical conditions supporting the original approval still hold.

If Ethics Approval Is Suspended or Terminated

Frequently Asked Questions About Suspension and Termination of Ethics Approval

Ethics Approval Can Remain Conditional on How the Study Actually Unfolds

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.